Physicochemical properties of SARS-CoV-2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control.
Animals
Betacoronavirus
/ chemistry
Disinfectants
/ pharmacology
Electrophoresis
Hot Temperature
Humans
Hydrogen-Ion Concentration
Isoelectric Point
SARS-CoV-2
Ultraviolet Rays
Vaccines, Attenuated
/ immunology
Viral Proteins
/ chemistry
Viral Vaccines
/ immunology
Virus Inactivation
/ radiation effects
COVID-19
Formulation
Physicochemical properties
SARS-CoV
Vaccine
Journal
Electrophoresis
ISSN: 1522-2683
Titre abrégé: Electrophoresis
Pays: Germany
ID NLM: 8204476
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
08
05
2020
revised:
22
05
2020
accepted:
22
05
2020
pubmed:
30
5
2020
medline:
1
8
2020
entrez:
30
5
2020
Statut:
ppublish
Résumé
The material properties of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its proteins are discussed. We review the viral structure, size, rigidity, lipophilicity, isoelectric point, buoyant density and centrifugation conditions, stability against pH, temperature, UV light, gamma radiation, and susceptibility to various chemical agents including solvents and detergents. Possible inactivation, downstream, and formulation conditions are given including suitable buffers and some first ideas for quality-control methods. This information supports vaccine development and discussion with competent authorities during vaccine approval and is certainly related to drug-targeting strategies and hygienics. Several instructive tables are given, including the pI and grand average of hydropathicity (GRAVY) of SARS-CoV-1 and -2 proteins in comparison. SARS-CoV-1 and SARS-CoV-2 are similar in many regards, so information can often be derived. Both are unusually stable, but sensitive at their lipophilic membranes. However, since seemingly small differences can have strong effects, for example, on immunologically relevant epitope settings, unevaluated knowledge transfer from SARS-CoV-1 to SARS-CoV-2 cannot be advised. Published knowledge regarding downstream processes, formulations and quality assuring methods is, as yet, limited. However, standard approaches employed for other viruses and vaccines seem to be feasible including virus inactivation, centrifugation conditions, and the use of adjuvants.
Identifiants
pubmed: 32469436
doi: 10.1002/elps.202000121
pmc: PMC7283733
doi:
Substances chimiques
Disinfectants
0
Vaccines, Attenuated
0
Viral Proteins
0
Viral Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1137-1151Informations de copyright
© 2020 The Authors. Electrophoresis published by Wiley-VCH Verlag GmbH & Co. KGaA.
Références
Curr Protoc Microbiol. 2011 May;Chapter 15:Unit 15E.1
pubmed: 21538303
J Hosp Infect. 2020 Mar;104(3):246-251
pubmed: 32035997
J Virol. 2006 Aug;80(16):7918-28
pubmed: 16873249
J Virol Methods. 2004 Oct;121(1):85-91
pubmed: 15350737
Virus Res. 2005 May;109(2):191-202
pubmed: 15763150
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Protein Sci. 2020 Jul;29(7):1596-1605
pubmed: 32304108
Pharmacol Res Perspect. 2020 Dec;8(6):e00674
pubmed: 33124786
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Int J Biol Sci. 2020 Apr 6;16(11):1846-1860
pubmed: 32398954
Plant Sci. 2001 Apr;160(5):1025-1033
pubmed: 11297800
Acta Pharm Sin B. 2020 May;10(5):766-788
pubmed: 32292689
Int J Biochem Cell Biol. 2006;38(4):589-99
pubmed: 16343974
Chin Med J (Engl). 2005 May 5;118(9):707-13
pubmed: 15899130
Methods Mol Biol. 2016;1403:269-84
pubmed: 27076136
Electrophoresis. 2013 Jun;34(11):1600-9
pubmed: 23483563
J Virol. 2003 Dec;77(23):12543-51
pubmed: 14610177
Antiviral Res. 2011 Nov;92(2):204-12
pubmed: 21854807
Vaccine. 2005 Aug 15;23(35):4385-91
pubmed: 16005746
Methods Mol Biol. 2015;1282:99-108
pubmed: 25720475
J Sep Sci. 2007 Jul;30(11):1704-13
pubmed: 17623450
Int J Mass Spectrom. 2007 Dec 1;268(2):296-303
pubmed: 32288628
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Cell. 2020 May 14;181(4):914-921.e10
pubmed: 32330414
Infect Dis Poverty. 2020 Sep 16;9(1):132
pubmed: 32938504
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Acta Pharmacol Sin. 2003 Jun;24(6):505-11
pubmed: 12791175
Virol J. 2019 May 27;16(1):69
pubmed: 31133031
Transfusion. 2006 Oct;46(10):1770-7
pubmed: 17002634
Electrophoresis. 2013 Jun;34(12):1812-9
pubmed: 23765862
Viral Immunol. 2010 Oct;23(5):509-19
pubmed: 20883165
J Virol Methods. 2005 Nov;129(2):152-61
pubmed: 16023741
Biochemistry. 2004 Aug 31;43(34):11103-8
pubmed: 15323569
Electrophoresis. 2008 Jun;29(12):2578-86
pubmed: 18576409
J Virol. 2015 Mar;89(6):2995-3007
pubmed: 25520500
Expert Rev Vaccines. 2012 Jun;11(6):695-719
pubmed: 22873127
FEBS Lett. 2004 Oct 8;576(1-2):174-8
pubmed: 15474033
Protein Sci. 2014 May;23(5):603-17
pubmed: 24519901
Science. 2020 May 8;368(6491):630-633
pubmed: 32245784
Vaccine. 2011 Sep 2;29(38):6606-13
pubmed: 21762752
Nat Rev Drug Discov. 2020 May;19(5):305-306
pubmed: 32273591
Med Microbiol Immunol. 2005 Jan;194(1-2):1-6
pubmed: 15118911
Expert Rev Vaccines. 2009 Jul;8(7):887-98
pubmed: 19538115
J Hosp Infect. 2005 Oct;61(2):107-11
pubmed: 15923059
Nucleic Acids Res. 2003 Jul 1;31(13):3784-8
pubmed: 12824418
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
Expert Rev Vaccines. 2012 Dec;11(12):1405-13
pubmed: 23252385
Vaccines (Basel). 2020 Mar 29;8(2):
pubmed: 32235387
Nat Struct Mol Biol. 2006 Aug;13(8):751-2
pubmed: 16845391
J Pharm Anal. 2020 Aug;10(4):313-319
pubmed: 32296570
Vaccine. 2014 May 30;32(26):3169-3174
pubmed: 24736006
J Virol. 2006 Jan;80(1):210-7
pubmed: 16352545
J Struct Biol. 2011 Apr;174(1):11-22
pubmed: 21130884
Virusdisease. 2020 Mar;31(1):13-21
pubmed: 32206694
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Talanta. 2017 May 1;166:8-14
pubmed: 28213262
Langmuir. 2020 Jan 14;36(1):370-378
pubmed: 31845814
PeerJ. 2020 Jul 27;8:e9572
pubmed: 33194329
Nucleic Acids Res. 2017 Jan 4;45(D1):D1112-D1116
pubmed: 27789699
Lancet Microbe. 2020 May;1(1):e10
pubmed: 32835322
Vaccine. 2006 Feb 13;24(7):1028-34
pubmed: 16388880
J Virol. 2008 Apr;82(7):3220-35
pubmed: 18199635
Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12543-7
pubmed: 16116101
PLoS Pathog. 2009 Jul;5(7):e1000511
pubmed: 19593379
J Biosci Bioeng. 2014 Sep;118(3):311-4
pubmed: 24694399
Cell Mol Immunol. 2020 May;17(5):536-538
pubmed: 32132669
Biologicals. 2005 Jun;33(2):95-9
pubmed: 15939287
N Engl J Med. 2020 Apr 16;382(16):1564-1567
pubmed: 32182409
J Pharm Biomed Anal. 2015 Mar 25;107:311-7
pubmed: 25638307
Clin Microbiol Rev. 1999 Jan;12(1):147-79
pubmed: 9880479
Dermatology. 2006;212 Suppl 1:119-23
pubmed: 16490989
J Appl Microbiol. 2010 Aug;109(2):388-397
pubmed: 20102425
Immunity. 2020 Apr 14;52(4):583-589
pubmed: 32259480
Electrophoresis. 2019 Sep;40(18-19):2277-2284
pubmed: 30951206